Syndax Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable
Syndax Pharmaceuticals, Inc. (SNDX) reported Increase (Decrease) in Accounts Receivable of $7.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $7.19M, a 92.68% increase year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$120.00K, a 101.48% decline year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $12.59M, a 65.65% increase year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $5.95M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $30.39M, a 299.82% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $7.60M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $7.07M 10-Q · filed 2026-08-04 | $19.66M derived: sum of 3 quarters · filed 2026-08-04 | $25.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$120.00K 10-Q · filed 2026-04-30 | $12.47M derived: sum of 2 quarters · filed 2026-04-30 | $18.42M derived: sum of 3 quarters · filed 2026-04-30 | $22.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $12.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.54M derived: sum of 2 quarters · filed 2026-02-26 | $22.27M derived: sum of 3 quarters · filed 2026-08-04 | $30.39M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $9.68M derived: sum of 2 quarters · filed 2026-08-04 | $17.80M 10-Q · filed 2025-11-03 | $25.40M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $11.85M 10-Q · filed 2026-08-04 | $19.45M derived: sum of 3 quarters · filed 2026-08-04 | $19.45M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $8.12M 10-Q · filed 2026-04-30 | $15.72M derived: sum of 2 quarters · filed 2026-04-30 | $15.72M derived: sum of 3 quarters · filed 2026-04-30 | $15.72M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.60M derived: sum of 2 quarters · filed 2026-02-26 | $7.60M derived: sum of 3 quarters · filed 2026-02-26 | $7.60M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $0.00 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |